D. Fermin

inhibitor of the ERK cascade, in the human heart Identification and regulation of Sprouty1, a negative

Jennifer L Hall, L. Miller, S. Grindle, 2016 .

Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart.

Jennifer L Hall, L. Miller, S. Grindle, 2004, Physiological genomics.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

S. Solomon, M. Wheeler, T. Seidler, 2020, The Lancet.

Physician radiation exposure during endomyocardial biopsy and right heart catheterization.

R. Madder, J. Parker, R. Loyaga-Rendon, 2022, Journal of cardiac failure.

The Pregnancy Heart Team Approach for the Adult with Hypertrophic Cardiomyopathy and Severe Left Ventricular Outflow Tract Obstruction

Bennett P. Samuel, Stephen C Cook, V. Romero, 2020 .

Sex and Age Dimorphism of Myocardial Gene Expression in Nonischemic Human Heart Failure

S. Hannenhalli, C. D. dos Remedios, F. Pagani, 2008, Circulation. Cardiovascular genetics.

Clinical, molecular, and genomic changes in response to a left ventricular assist device.

M. Slaughter, L. Miller, H. Baba, 2011, Journal of the American College of Cardiology.

Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks.

Xinqiang Han, Suzanne Grindle, Robert D Simari, 2004, Physiological genomics.

Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices

Sangjin Lee, R. Loyaga-Rendon, D. Fermin, 2017, Current Heart Failure Reports.

Changes in heart transplant waitlist and posttransplant outcomes in patients with restrictive and hypertrophic cardiomyopathy with the new heart transplant allocation system

Sangjin Lee, S. Jovinge, M. Leacche, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY

M. Wheeler, T. Abraham, D. Zwas, 2021 .

Changing Landscape of Heart Transplantation in the US after Implementation of the New Allocation System: A UNOS Data Registry Analysis.

S. Jovinge, M. Leacche, R. Loyaga-Rendon, 2020, The Journal of Heart and Lung Transplantation.

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.

N. Smedira, M. Desai, H. Schaff, 2023, JAMA cardiology.